Bloodstream infections leading to sepsis are among the top 10 causes of mortality in the United States. It is commonly recognized that rapid identification and therapy can have a tremendous impact on patient recovery and hospital length of stay.
Data collected over a five year period will be reviewed to demonstrate the impact of migrating from traditional microbiology methods to a rapid molecular diagnostic test, and the drivers behind the adoption of the ePlex® Blood Culture Identification Panels.
Register for this event to learn more about the impact of rapid molecular diagnostic testing for bloodstream infections.
Kevin M. McNabb, PhD, MT
Director of Microbiology, Immunology and Molecular Testing
Wilmington Pathology Associates, New Hanover Regional Medical Center